Clinical trials · Hartford, CT
Advanced or Metastatic Solid Tumors clinical trials in Hartford
We’re tracking 196 recruiting advanced or metastatic solid tumors studies with a site in or near Hartford — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Hartford
- NCT07226349RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug, BG-75098, alone or with other treatments, for adults with advanced solid tumors that have spread or cannot be removed. It may be an option if you have already tried standard treatments or if they are not suitable for you.
New Haven, ConnecticutAges 18 years+ - NCT05983432RecruitingPhase 1
Study of BL-B01D1 for advanced lung and other solid tumors
This trial tests an experimental drug called BL-B01D1 for people with several types of advanced solid tumors, especially non-small cell lung cancer and breast cancer. It's designed for those whose cancer has continued to grow after standard treatments.
New Haven, ConnecticutAges 18 years+ - NCT06625593RecruitingPhase 1
Study of BG-C137 for advanced solid tumors
This trial tests a new drug called BG-C137 for people with advanced solid tumors that have stopped responding to other treatments. The drug targets a protein called FGFR2b found on some cancer cells, aiming to deliver a therapy directly to the tumor.
New Haven, ConnecticutAges 18 years+ - NCT06998407RecruitingPhase 1/Phase 2
Study of AVZO-023 for advanced solid tumors
This trial tests a new drug, AVZO-023, alone or with other treatments, for people with advanced solid tumors that have not responded to standard therapy. The goal is to see if it can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT07098988RecruitingPhase 2
Visugromab plus standard chemo-immunotherapy for lung cancer
This trial tests an experimental drug called visugromab added to standard chemotherapy and immunotherapy for people newly diagnosed with advanced non-squamous lung cancer. It aims to see if the combination works better than standard treatment alone.
New Haven, ConnecticutAges 18 years+ - NCT06941272RecruitingPhase 1/Phase 2
Study of patritumab deruxtecan for children with hard-to-treat solid tumors
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
New Haven, ConnecticutAges 1 month–17 years - NCT06172478RecruitingPhase 2
HER3-DXd for advanced solid tumors after prior treatment
This trial tests a new targeted drug called HER3-DXd for people with several types of advanced solid tumors that have stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver chemotherapy directly to cancer cells that have a protein called HER3 on their surface.
New Haven, ConnecticutAges 18 years+ - NCT06982521RecruitingPhase 3
Comparing two drug combinations for advanced breast cancer
This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.
New Haven, ConnecticutAges 18 years+ - NCT07042100RecruitingPhase 1
Safety study of SBO-154 for advanced solid tumors
This trial tests a new drug called SBO-154 to see if it is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. It may be an option if you have few or no other treatment choices.
New Haven, ConnecticutAges 18 years+ - NCT05007782RecruitingPhase 1
Testing a new immune drug for advanced solid tumors
This Phase 1 study tests denikitug (GS-1811) alone or with zimberelimab in adults with advanced solid tumors. It’s looking mainly at safety and how the treatment works in people whose cancer has already been treated—or is not treatable with standard options.
New Haven, ConnecticutAges 18 years+ - NCT06906562RecruitingPhase 2
Pemigatinib for advanced pancreatic cancer with FGFR changes
This trial tests a targeted pill, pemigatinib, for people with advanced pancreatic cancer that has a specific FGFR gene change. The study is done entirely through telemedicine, so you can participate from home if eligible.
New Haven, ConnecticutAges 18 years+ - NCT06324357RecruitingPhase 1/Phase 2
Zongertinib for HER2-positive cancers that have spread
This trial tests a new pill called zongertinib, alone or with other drugs, for people with HER2-positive cancers (like breast, stomach, or colorectal cancer) that have spread and are no longer responding to standard treatments. The goal is to find the best dose and see if it can help shrink tumors or slow the disease.
New Haven, ConnecticutAges 18 years+ - NCT06917079RecruitingPhase 1
BBO-11818 for KRAS-mutated cancers
This trial tests a new oral drug (BBO-11818) for people with solid tumors that have a specific KRAS mutation. It's for those whose cancer has spread or cannot be removed by surgery and who have not had other cancers recently.
New Haven, ConnecticutAges 18 years+ - NCT07758816Recruiting
Better treatments for Gaucher disease with lung or bone problems
This study looks at how standard treatments for Gaucher disease affect lung problems, bone damage, and parkinson-like symptoms. It aims to find better ways to treat these complications and improve quality of life.
New Haven, ConnecticutAges 3 months–75 years - NCT07293351RecruitingPhase 1/Phase 2
Testing pumitamig with other drugs for advanced kidney cancer
This study tests a new drug (pumitamig) alone or with ipilimumab or cabozantinib for advanced kidney cancer that cannot be removed by surgery. It aims to find effective treatment options for people whose cancer has spread or is locally advanced.
New Haven, ConnecticutAges 18 years+ - NCT06994806RecruitingPhase 1
KQB168 for advanced solid tumors post immunotherapy
This trial tests a new oral drug (KQB168) given alone or with other medicines for people with advanced solid tumors that have not responded to immunotherapy. The goal is to see if it is safe and can help shrink or slow the growth of cancer.
New Haven, ConnecticutAges 18 years+ - NCT05808634RecruitingPhase 1
Testing an investigational drug for advanced lung or gut cancer
This Phase 1 trial tests BA3182, an investigational medicine, in people with advanced adenocarcinoma that cannot be removed by surgery. The goal is to see how the treatment works and whether it’s tolerated, and it may offer an option when standard options have been limited.
New Haven, ConnecticutAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
New Haven, ConnecticutAges 18 years+ - NCT07218003Enrolling by invitationPhase 1
Study of RNDO-564 alone or with pembrolizumab for bladder cancer
This trial tests an experimental drug, RNDO-564, either by itself or combined with another drug (pembrolizumab), for people with advanced bladder cancer or other solid tumors that have stopped responding to standard treatments. The goal is to see if it can shrink tumors or slow cancer growth.
New Haven, ConnecticutAges 18 years+ - NCT07416123RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests an experimental drug, GEN1106, for people with solid tumors that have not responded to standard treatments. It aims to see if the drug can help shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT07079631RecruitingPhase 1/Phase 2
Testing BNT314 with pumitamig and chemo for advanced colorectal cancer
This trial tests a new combination of drugs (BNT314 and pumitamig) plus chemotherapy for people with advanced colorectal cancer that has not responded to prior treatments. The goal is to see if this combination is safe and helps shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT05867251RecruitingPhase 1/Phase 2
AVZO-021 for advanced breast and ovarian cancers
This early-stage study tests AVZO-021, a new anti-cancer medicine, in people with advanced solid tumors like specific types of breast and ovarian (or related) cancers. It’s meant to find the safest dose and look for signs the medicine can shrink tumors, especially in cancers with certain gene changes.
New Haven, ConnecticutAges 18 years+ - NCT07090499RecruitingPhase 1
Study of PF-08046876 for advanced solid tumors
This trial tests a new medicine, PF-08046876, for people with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas. It aims to see if the drug is safe and works against these cancers.
New Haven, ConnecticutAges 18 years+ - NCT06597721RecruitingPhase 1
ADCE-T02 for advanced solid tumors
This trial tests a new drug called ADCE-T02, which is an antibody-drug conjugate designed to target and deliver a chemotherapy payload to cancer cells that have a protein called tissue factor. The study is for people with advanced solid tumors that have not responded to other treatments, and it aims to see if the drug is safe and effective.
New Haven, ConnecticutAges 18 years+
Hear when a new Advanced or Metastatic Solid Tumors trial opens near Hartford, CT
We’ll email you when one opens near Hartford, CT — at most once a week, no account needed, unsubscribe anytime.
Advanced or Metastatic Solid Tumors trials in other cities
Where these studies are running near Hartford
Institutions with a site for the recruiting advanced or metastatic solid tumors studies listed above.
- Yale Cancer Center · 14 studies
- Yale University · 2 studies
- Avenzo Therapeutics Recruiting Site
- Exelixis Clinical Site
- Local Institution
- Ohio State University-Telemedicine
- Smilow Cancer Center
- Smilow Cancer Hospital
What taking part in a advanced or metastatic solid tumors study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting advanced or metastatic solid tumors studies in Connecticut.
Common questions
- Are there advanced or metastatic solid tumors clinical trials near Hartford?
- Yes. We're currently tracking 196 recruiting advanced or metastatic solid tumors studies with a site near Hartford, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a advanced or metastatic solid tumors study near Hartford?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Hartford to take part?
- Not necessarily. These studies have a site near Hartford, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New advanced or metastatic solid tumors studies open near Hartford regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.